Literature DB >> 31126876

Role of osteopontin in dendritic cell shaping of immune responses.

Annalisa Del Prete1, Sara Scutera2, Silvano Sozzani3, Tiziana Musso2.   

Abstract

Osteopontin (OPN) is a pleiotropic cytokine produced both by immune and non-immune cells and active on different cellular targets. OPN production has been associated with several pathological conditions, including autoimmune diseases (e.g. lupus, multiple sclerosis and rheumatoid arthritis) and cancer. Emerging evidence suggests that the role of OPN has been underestimated, as it seems to be working at multiple levels of immune regulation, such as the shaping of T cell effector responses, the regulation of the tumor microenvironment, and the functional interaction with mesenchymal stromal cells. In this context, dendritic cells (DCs) play a crucial role being both an important source and a cellular target for OPN action. DC family is composed by several cell subsets endowed with specific immune functions. OPN exerts its biological functions through multiple receptors and is produced in different intracellular and secreted forms. OPN production by DC subsets is emerging as a crucial mechanism of regulation in normal and pathological conditions and starts to be exploited as a therapeutic target. This review will focus on the role of DC-derived OPN in shaping immune response and on the complex role of this cytokines in the regulation in immune response.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmune diseases; Cancer; Dendritic cells; Mesenchymal stromal cells; Osteopontin; T cell polarization

Year:  2019        PMID: 31126876     DOI: 10.1016/j.cytogfr.2019.05.004

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  8 in total

1.  Bartonella henselae Persistence within Mesenchymal Stromal Cells Enhances Endothelial Cell Activation and Infectibility That Amplifies the Angiogenic Process.

Authors:  Sara Scutera; Stefania Mitola; Silvano Sozzani; Tiziana Musso; Rosaria Sparti; Valentina Salvi; Elisabetta Grillo; Giorgia Piersigilli; Mattia Bugatti; Daniela Alotto; Tiziana Schioppa
Journal:  Infect Immun       Date:  2021-07-15       Impact factor: 3.441

Review 2.  Osteopontin and Transplantation: Where Are We Now?

Authors:  Beata Kaleta
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-05-21       Impact factor: 4.291

Review 3.  The Yin-Yang of osteopontin in nervous system diseases: damage versus repair.

Authors:  Giuseppe Cappellano; Domizia Vecchio; Luca Magistrelli; Nausicaa Clemente; Davide Raineri; Camilla Barbero Mazzucca; Eleonora Virgilio; Umberto Dianzani; Annalisa Chiocchetti; Cristoforo Comi
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

4.  Higher Expression of SPP1 Predicts Poorer Survival Outcomes in Head and Neck Cancer.

Authors:  Tongwu Bie; Xuewen Zhang
Journal:  J Immunol Res       Date:  2021-12-23       Impact factor: 4.818

5.  Gene Expression Patterns of Osteopontin Isoforms and Integrins in Malignant Melanoma.

Authors:  Krisztina Jámbor; Viktória Koroknai; Tímea Kiss; István Szász; Péter Pikó; Margit Balázs
Journal:  Pathol Oncol Res       Date:  2022-08-24       Impact factor: 2.874

6.  A Four-Gene Signature Associated with Radioresistance in Head and Neck Squamous Cell Carcinoma Identified by Text Mining and Data Analysis.

Authors:  Yongqian Zhang; Hongmin Wang; Feifei Wang; Wenhua Ma; Na Li; Changwen Bo; YingChun Zhao; Li He; Ming Liu
Journal:  Comput Math Methods Med       Date:  2022-09-27       Impact factor: 2.809

Review 7.  P2X7 receptor as the regulator of T-cell function in intestinal barrier disruption.

Authors:  Zhi-Feng Jiang; Wei Wu; Han-Bing Hu; Zheng-Yang Li; Ming Zhong; Lin Zhang
Journal:  World J Gastroenterol       Date:  2022-09-28       Impact factor: 5.374

8.  CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.

Authors:  Damiano Marastoni; Roberta Magliozzi; Anna Bolzan; Anna Isabella Pisani; Stefania Rossi; Francesco Crescenzo; Stefania Montemezzi; Francesca Benedetta Pizzini; Massimiliano Calabrese
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.